Logo

Stuart Pollard, Donna Ward, Jorgine Ellerbrock

Nov 20, 2007
Premium
Alnylam Pharmaceuticals has expanded its management team to include Stuart Pollard as vice president of scientific and business strategy, and Donna Ward as vice president of intellectual property.
 
Pollard previously held various scientific and business development roles at Maxygen, including CSO. Before this, he worked for Biogen Idec, an Alnylam collaborator (see RNAi News, 9/21/2006).

 

He holds a PhD in molecular virology from the University of Reading.
 
Ward comes to Alnylam from Elmore Patent Law Group, where she was a patent attorney representing biotech and pharmaceutical clients. Before this, she worked for Isis Pharmaceuticals, also an Alnylam collaborator.
 
She holds a JD from the Thomas Jefferson School of Law, as well as a PhD in biochemistry from the University of Kentucky.
 
 
Gen-Probe has named Jorgine Ellerbrock senior vice president of operations.
 
Ellerbrock previously worked at Invitrogen as vice president of operations. She has also held various positions at GE Healthcare Bio-science and Amersham.
 
She has BS in microbiology and an MBA from San Diego State University.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.